Birchview Capital LP Reduces Position in Oxford Immunotec Global PLC (OXFD)
Birchview Capital LP reduced its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 19.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 80,303 shares of the company’s stock after selling 20,000 shares during the period. Oxford Immunotec Global comprises approximately 1.0% of Birchview Capital LP’s holdings, making the stock its 11th largest holding. Birchview Capital LP owned about 0.30% of Oxford Immunotec Global worth $1,026,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Engineers Gate Manager LP acquired a new stake in shares of Oxford Immunotec Global during the 3rd quarter valued at approximately $188,000. Renaissance Technologies LLC raised its position in shares of Oxford Immunotec Global by 84.7% during the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock valued at $271,000 after acquiring an additional 9,658 shares in the last quarter. Trexquant Investment LP acquired a new stake in Oxford Immunotec Global in the third quarter worth $279,000. Rhumbline Advisers increased its position in Oxford Immunotec Global by 50.7% in the fourth quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock worth $419,000 after buying an additional 11,022 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Oxford Immunotec Global in the third quarter worth $445,000. 91.20% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Peter Wrighton-Smith sold 10,000 shares of the stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $14.91, for a total value of $149,100.00. Following the completion of the transaction, the chief executive officer now owns 423,469 shares of the company’s stock, valued at $6,313,922.79. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $14.25, for a total value of $42,750.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $85,500. The disclosure for this sale can be found here. 6.61% of the stock is owned by company insiders.
Shares of NASDAQ OXFD opened at $14.94 on Wednesday. Oxford Immunotec Global PLC has a 1-year low of $10.00 and a 1-year high of $19.19. The firm has a market capitalization of $387.51 million, a price-to-earnings ratio of -10.99 and a beta of 0.33.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2019/02/13/birchview-capital-lp-reduces-position-in-oxford-immunotec-global-plc-oxfd.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Further Reading: Trading Strategy Examples and Plans
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.